Oral iron tolerance

A. B. S. Mitchell
M.B., M.R.C.P.

Charing Cross Hospital, London

Summary
The tolerance of volunteer patients to various ferrous salt preparations, administered orally in equivalent doses of elemental iron, has been compared. The palatability of ferrous sulphate tablets, BP, given before meals was not improved by administration after meals, by sustained release formulation, or by substituting other ferrous salts. Intolerance was related to the number of tablets rather than to the dose of iron in a course. The liquid iron preparation was the least acceptable.

Ferrous sulphate tablets, BP, given before meals, approximate most closely to the hypothetical ideal iron preparation for therapeutic oral administration.

Introduction
Iron deficiency is common, and can be corrected by means of orally administered iron in most patients. The variety of oral iron preparations available suggests that there is no single ideal. This should be palatable and free of unwanted effects, cheap, well absorbed, and effective in raising the haemoglobin concentration in patients suffering from uncomplicated iron-deficiency anaemia.

Most ferrous salts are well absorbed when compared with ferric salts (Brise and Hallberg, 1962; Hallberg, 1970), and the side effects of reduced iron have been considered to be related to the dose and not to the particular salt used (Hallberg, Ryttinger and Sölvell, 1966; Sölvell, 1970). The optimum dose of oral iron for therapy is not defined. The amount absorbed continues to increase as the dose increases, while the ratio of absorbed to ingested iron falls when doses of oral iron are increased (Bothwell, Pirro-Birol and Finch, 1958; Smith and Panacchialli, 1958; Beutler, Kelly and Beutler, 1962; Middleton, Nagy and Morrison, 1966). As the incidence of side effects of oral iron increases when the total daily dose is increased (Hallberg et al., 1966; Sölvell, 1970), the optimum is probably the maximum that can be ingested without producing side effects and, hence, defaulting.

Attempts have been made to reduce the incidence of side effects by means of sustained release preparations. As most iron absorption occurs in the upper small intestine, delaying the release of iron might well decrease absorption and this has been demonstrated in some studies (Bothwell et al., 1958; Crosland-Taylor, Keeling and Cromie, 1965; Middleton et al., 1966; Sölvell and Norrby, 1970) but not in all (Layrisse, 1963; McCurdy and Dern, 1968). Nevertheless, sustained release preparations have been shown to raise the haemoglobin concentration satisfactorily in some studies (Pote, 1958; Webster, 1962; Layrisse, 1963; Israels and Cook, 1965; Gomez and Gomez, 1967, 1969; Howard, 1970) but not in all (Beutler and Meerkreebs, 1966; Mitchell and Gill, 1974). Although increases in the haemoglobin concentration are the objective of treatment, there is considerable individual variation in the response to therapy, which is a relatively insensitive index of effect (Brise and Hallberg, 1962; Crosland-Taylor et al., 1965; Hallberg, 1970).

Perhaps the difference between the direct tests of absorption and the haematological response can be explained by the time of administration of the sustained release forms—fasting or unrelated to meals. Brise and Hallberg (1962) showed that iron taken with food is absorbed about half as well as that taken between meals. It has been considered impracticable to give ferrous sulphate tablets, BP, unrelated to meals, because of the anticipated side effects (Israels and Cook, 1965), but ferrous fumarate administered to fasting subjects has been shown to be as effective and with as few side effects as a sustained release form of ferrous sulphate (Callender, 1969). Ferrous fumarate is less soluble than ferrous sulphate, and has been reported to be as well (Brise and Hallberg, 1962) or less well (Callender and Warner, 1969) absorbed. An enhanced response might therefore, be expected from ferrous sulphate administered to fasting subjects.

In this trial the acceptability of ferrous sulphate tablets, BP, given before or after meals, has been compared with sustained release preparations of this compound, with various other reduced iron salts, and with a placebo.

Present address: Dr A. B. S. Mitchell, Consultant Physician, Prince of Wales Hospital, London N15 4AW.
Patients and methods
The patients were incapacitated by crippling rheumatoid arthritis and were being cared for in a residential hospital. Those who had experience of oral iron therapy were asked to volunteer for this study; fourteen did so, and completed the trial.

Nine preparations of iron were exhibited, each for a 6-day course. The dose of elemental iron averaged 100 mg daily for the first 3 days, and 200 mg daily for the next 3 days; no therapy was offered on the seventh day. The iron preparations used were those available commercially, the dose of elemental iron being adjusted by varying the number of tablets (or capsules, or teaspoonfuls) offered (Table 1). Lactose tablets were offered for two periods, before one of which the patients were told that the tablets consisted of lactose and would indicate their ability to take tablets, and before the other they were told that an iron preparation had been made to resemble the lactose tablets (hereafter referred to as the placebo tablets). The number of lactose tablets offered was the same as the number of ferrous sulphate tablets, BP. All the sustained release preparations of ferrous sulphate, and one course of ferrous sulphate tablets, BP, were given before meals; all other preparations were given after meals. The order in which the preparations were offered during the 12 weeks of the trial was decided by reference to a table of random digits.

The patient volunteers knew that the trial was to discover which preparations were the more acceptable, and they were told that should any upset occur they could stop taking the treatment. The acceptability of the iron preparations was then calculated by assessing the proportion of iron taken relative to that offered. In the case of the lactose tablets this proportion related to tablets.

Results

Patients
As perhaps was to be expected with patients who freely volunteered for the trial, most took a high proportion of the preparations presented (expressed as percentages: range 71.0–95.9, mean 86.2, ±6.85), and only one of the fourteen took significantly less than the mean (at the 95% level of confidence).

Duration
The trial extended over 12 weeks and the proportion taken in any week remained high (expressed as percentages: range 69.4–95.9, mean 86.1, ±6.54), only the last 2 weeks differing significantly from the mean (69.4% and 72.8% respectively). This was probably due to the patients' tiring of the trial. No preparation was given with undue frequency during this period, so the result was not biased. The proportion taken during the first week was also lower than the mean (74.9%) but not significantly.

Preparations
The proportion of each preparation taken to that offered is shown in the bar chart (Fig. 1). The mean proportion taken of all preparations presented was 86.2% (±6.35%), and only two preparations differed significantly from this—ferrous gluconate elixir (61.1%) and ferrous calcium citrate (70.8%).

Discussion
Any substance administered to patients may have unwanted side effects, even when that substance is pharmacologically inert (Green, 1964). The findings in this study confirm this observation, in that neither of the courses of lactose tablets was completely acceptable. The lactose and the placebo tablets were

<table>
<thead>
<tr>
<th>Iron preparation</th>
<th>Dose of elemental iron (mg) per tablet or capsule</th>
<th>Number per course—tablets or capsules</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferrous fumarate (Fersamel)</td>
<td>65</td>
<td>14</td>
</tr>
<tr>
<td>Ferrous sulphate tablets, BP</td>
<td>60</td>
<td>15</td>
</tr>
<tr>
<td>Ferrous succinate (Ferromyn)</td>
<td>37</td>
<td>25</td>
</tr>
<tr>
<td>Ferrous gluconate tablets, BP</td>
<td>26</td>
<td>25</td>
</tr>
<tr>
<td>Ferrous calcium citrate (Rarical)</td>
<td>25</td>
<td>36</td>
</tr>
<tr>
<td>Sustained release preparations of ferrous sulphate:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feospan</td>
<td>45</td>
<td>20</td>
</tr>
<tr>
<td>Slow-Fe</td>
<td>50</td>
<td>18</td>
</tr>
<tr>
<td>Ferro-Gradumet</td>
<td>105</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>per teaspoonful (5 ml) tealosefuls</td>
<td></td>
</tr>
<tr>
<td>Ferrous gluconate elixir (Feolucon)</td>
<td>29</td>
<td>32</td>
</tr>
</tbody>
</table>
equally acceptable, in contradistinction to the findings of a similar study in which the lactose tablets produced virtually no side effects (Kerr and Davidson, 1958b). This can probably be attributed to the difference between the populations investigated; young, healthy nurses in the study of Kerr and Davidson (1958b) and elderly rheumatoid cripples in this study. Green (1964) found that placebos tended to increase the incidence of symptoms already present, and that these increased in frequency with age and disease.

The acceptability of the placebo tablets was also much the same as that of most iron preparations, a finding similar to that in other studies (Kerr and Davidson, 1958a, b). This could suggest that the side effects of oral iron therapy were due rather to the taking of tablets than to their content, and are psychological in origin, as has been suggested (Girdwood, 1952). However, not all studies agree with this; for example Sölvell (1970) found that oral therapy resulted in more side effects than did a placebo.

When the different preparations of iron in tablet form are compared, a significant inverse relationship is found between the number of tablets prescribed and those ingested (Fig. 2). This agrees with the finding that as the placebo dose increases so does the incidence of side effects (Green, 1964) and the frequency of defaulting (Maddox, 1967). Hence, those preparations containing more elemental iron per tablet have an advantage in regard to acceptability, when equivalent iron doses are administered. An apparent greater acceptability of tablets containing smaller amounts of elemental iron might be due to the smaller doses of iron taken, should a standard number of tablets be prescribed.

Only the proportion of ferrous calcium citrate ingested differed significantly from the mean proportion of all the solid preparations presented. This tablet contained the smallest amount of elemental iron per tablet and, therefore, the largest number of tablets had to be ingested. This iron salt is as well absorbed as other ferrous salts (Bothwell et al., 1958) and the preparation is formulated with tricalcium citrate as a supplement during pregnancy, and not for the treatment of iron-deficiency anaemia.

Other iron tablets in this trial were equally palatable. Notably, ferrous sulphate tablets, BP, given before meals were as acceptable as those given after meals, and as the three sustained release preparations of iron.

The only liquid preparation of iron, ferrous gluconate elixir, was significantly less acceptable than the tablets. The absorption of liquid preparations of ferrous salts is equivalent to that of plain, rapidly disintegrating tablets (Bothwell et al., 1958; Hallberg et al., 1966). As this liquid preparation is not as acceptable as tablets, it is suggested that its prescription should be reserved for patients who feel unable to take tablets, for those suffering from dysphagia and for those who, after gastric operations, require iron therapy but fail to respond to tablets of iron. Rapid gastric emptying after partial gastrectomy, and perhaps after vagotomy and drainage procedures, may reduce the absorption of iron.

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Mean acceptance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slow-Fe 96.8% a.c.</td>
<td>96.2%</td>
</tr>
<tr>
<td>Ferrous fumarate 96.1%</td>
<td></td>
</tr>
<tr>
<td>Lactose 95.2%</td>
<td></td>
</tr>
<tr>
<td>Ferrous sulphate tablets BP 93.0% a.c.</td>
<td></td>
</tr>
<tr>
<td>Placebo 92.4%</td>
<td></td>
</tr>
<tr>
<td>Ferro-Gradumet 90.2% a.c.</td>
<td></td>
</tr>
<tr>
<td>Ferrous sulphate tablets BP 88.1%</td>
<td></td>
</tr>
<tr>
<td>Ferrous succinate 87.2%</td>
<td></td>
</tr>
<tr>
<td>Feospan 85.7%</td>
<td></td>
</tr>
<tr>
<td>Ferrous gluconate tablets BP 77.7%</td>
<td></td>
</tr>
<tr>
<td>Ferrous calcium citrate 70.8%</td>
<td></td>
</tr>
<tr>
<td>Ferrous gluconate elixir 61.1%</td>
<td></td>
</tr>
</tbody>
</table>

Fig. 1. Bar chart showing the proportion of each iron preparation taken during the trial period (a.c. = before meals, all other preparations given with or after meals).

![Graph showing the correlation between number of tablets ingested and proportion of each iron preparation taken.](http://pmj.bmj.com/)

Fig. 2. Scatter diagram relating to proportion of each course to the number of tablets per course. Correlation coefficient, 0.8; $P < 0.001$. 

Downloaded from http://pmj.bmj.com/ on April 15, 2022 by guest. Protected.
Oral iron tolerance

705
tablets and yet allow a satisfactory response to iron in liquid form (Krause, 1966; Hallberg, 1970; Mitchell, 1974).

In a condition as common as iron-deficiency anaemia, the cost of therapy is significant. The therapeutic effect of oral iron therapy is related to the amount of elemental iron absorbed which is, itself, proportional to the dose of elemental iron ingested. The absorption of all the plain ferrous salts used in this investigation is equivalent, and that of sustained release preparations probably slightly less than that of the plain preparations. It is, therefore, reasonable to relate the price of each preparation to its content of elemental iron (Fig. 3). Ferrous sulphate tablets, BP, are the cheapest preparation.

As the side effects of oral iron are partly related to the total dose of elemental iron ingested, a method of reducing side effects while maintaining a therapeutic response, would be to stimulate absorption of the iron and hence decrease the ingestion/absorption ratio. Sorbitol and mannitol, when given in large amounts, have been shown to increase iron absorption but, unfortunately, also to increase the incidence of intolerance (Hallberg, Sölvell and Brise, 1966). Ascorbic acid has also been shown to promote iron absorption (Hallberg et al., 1966; McCurdy and Dern, 1968), but the combination of ascorbic acid and iron appeared to result in more side effects than did iron alone (Hallberg et al., 1966). Succinic acid is the most promising promoter of iron absorption, as it appears to increase iron absorption without an increase in side effects (Brise and Hallberg, 1962; Hallberg and Sölvell, 1966; Hallberg, 1970) and its use may be considered for the small proportion of patients who find side effects of oral iron therapy troublesome.

Acknowledgments

I would like to express my appreciation to Dr V. Kendall, the nursing staff, and the patient volunteers of the Royal Home and Hospital for Incurables, Putney. I should also like to thank Miss S. B. Down for the dispensing of the iron courses and their costing, Dr A. Fenton Lewis for invaluable help with the statistical analysis, and Mr A. N. Rollason for the design and preparation of charts.

References


Green, D.M. (1964) Pre-existing conditions, placebo reactions, and 'side effects'. Annals of Internal Medicine, 60, 255.


